Report
Martial Descoutures ...
  • Oussema Denguir

Cellectis : Agreement with Servier amended

>Amendment to its licence agreement with Servier - Cellectis has just announced an amendment to its initial agreement with Servier. This will allow Servier to obtain an exclusive worldwide license for the development and subsequent marketing of all products targeting CD19 (including ALLO-501A). In parallel, Cellectis will regain control over its five developments initially licensed to Servier but for which the targets had never been disclosed. On the financial s...
Underlying
Cellectis

Cellectis is a gene-editing company employing its core proprietary technologies to develop products in the field of immuno-oncology. UCART19 is Co.'s lead product. UCART19 is an engineered T-cell product which drives its ability to target and kill CD19-bearing cells, such as B-cell malignancies. Co. is also developing wholly-owned product candidates UCART123, UCARTCS1 and UCART38, which are in various stages of development. UCART 123, UCARTCS1 and UCART38 are engineered T-cell products that bear CARs that seek to kill cells expressing targets CD123, CS1 and CD38, respectively, which are found in other hematologic tumors, such as acute myeloid leukemia, or AML, and multiple myeloma, or MM.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Oussema Denguir

Other Reports on these Companies
Alfred Glaser ...
  • Charles Lepetitpas
  • Delphine Brault
  • Florent Laroche-Joubert
  • Louis Boujard, CFA
  • Martial Descoutures
  • Nicolas David
  • Oussema Denguir
  • Philippe Ourpatian
Other Reports from Oddo BHF
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch